Clinical trials: Malaria, Uncomplicated
Uncomplicated Plasmodium Falciparum
Momordica Charantia and Dihydroartemisinin-piperaquined-primaquine for Uncomplicated Plasmodium Falciparum Malaria Patients in Southwest Sumba Regency
Currently, the first-line combination of artemisinin, piperaquine and prima-quine is quite effective in controlling malaria, however, the threat of spread of drug-resistant parasites has been reported.
- Trial name
- MCHUPF (NCT05829187)
- Testing
- Dihydroartemisinin, Piperaquine, Primaquine
- Where
- Indonesia
- Volunteers
- 36 people
- Sponsor
- Syamsudin Abdillah,Ph.D, Pharm D
Malaria
Safety and Effectiveness of Artemisinin-based Combination Therapies (ACTs) With Repeated Treatments for Uncomplicated Falciparum Malaria Over a Three-year Period
A community-based, open-label, cluster-randomised longitudinal study in which children are randomized according to village health worker catchment areas comparing the safety and effectiveness of repeated treatments with…
- Trial name
- NCT01038063
- Testing
- Artemether-lumefantrine combination
- Where
- Malawi
- Volunteers
- 1,200 people
- Sponsor
- Liverpool School of Tropical Medicine
Malaria
Artemether-Lumefantrine (AL) Unit Dose Pre-packs Versus Blister Packs
The purpose of this study is to determine if adherence and effectiveness of AL in the treatment of uncomplicated malaria in children aged under five years using blister packs with pictorial leaflets can be at levels comparable to…
- Trial name
- NCT01065116
- Testing
- AL Blister-packs with Instruction leaflets, AL unit dose age specific pre-packs
- Where
- Uganda
- Volunteers
- 920 people
- Sponsor
- Malaria Consortium, Uganda
Malaria
Artesunate Plus Amodiaquine in Malaria in Cote d'Ivoire
The primary objective of this study is to demonstrate the non-inferiority of Polymerase Chain Reaction (PCR)-adjusted adequate clinical and parasitological response to artesunate plus amodiaquine at Day 28 in two groups of…
- Trial name
- NCT01023399
- Testing
- Artesunate + Amodiaquine
- Where
- Côte d’Ivoire
- Volunteers
- 580 people
- Sponsor
- Sanofi
Malaria
In Vivo and in Vitro Efficacy of Antimalarial Treatments in Children in Burkina Faso
Resistance to antimalarial drugs represents a major obstacle for controlling malaria in endemic countries, so that most sub-Saharan countries have changed their antimalarial drug policy to the new Artemisinin Containing…
- Trial name
- NCT00808951
- Testing
- Artesunate-amodiaquine, Artemether-lumefantrine
- Where
- Burkina Faso
- Volunteers
- 440 people
- Sponsor
- Centre Muraz
Malaria, Vivax, Therapeutics
DHA-PQP vs Chloroquine and Primaquine for Radical Cure of Vivax Malaria in Brazil
Plasmodium vivax can be cause of severe malaria and mortality. There are serious public health implications associated with cases of P.
- Trial name
- CuraVivax (NCT03208907)
- Testing
- CQ coadministered with PQ, DHA-PQP coadministered with PQ, CQ and PQ starting on Day 42
- Where
- Brazil
- Volunteers
- 419 people
- Sponsor
- Fundação de Medicina Tropical Dr. Heitor Vieira Dourado
Malaria
Impact of Artemisinin-based Combination Therapy and Quinine on Treatment Failure and Resistance in Uncomplicated Malaria
This is a bi-centric phase IIIb, randomized, open label, 3-arm clinical trial performed to investigate the impact of retreatment with an Artemisinin-Based Combination (ACT), for example Arthemeter-Lumefantrine (AL) in Uganda (Ug)…
- Trial name
- QuinAct (NCT01374581)
- Testing
- Artemether/Lumefantrine, Artesunate/Amodiaquine, Quinine + Clindamycin
- Where
- 2 sites in Republic of the Congo, Uganda
- Volunteers
- 2,117 people
- Sponsor
- Universiteit Antwerpen
Malaria
Efficacy of Artemisinin Combination Therapies for the Treatment of Uncomplicated P. Falciparum in Pregnancy in Brazil
Data on the burden of MIP in low transmission areas, such as Latin America, are very limited; there is even less information on the efficacy of case management of MiP.
- Trial name
- PAACT-PF (NCT01082731)
- Testing
- Artemether-Lumefantrine, Mefloquine- Artesunate
- Where
- 2 sites in Brazil
- Volunteers
- 6 people
- Sponsor
- Centers for Disease Control and Prevention
Malaria
Cohort Study in Uganda Comparing Artesunate + Amiodaquine (Coarsucam) Versus Artemether + Lumenfantrine (Coartem) in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks
Primary objective is to demonstrate the non-inferiority of PCR (Polymerase Chain Reaction) adjusted adequate clinical and parasitological response at Day 28 of Coarsucam versus Coartem, based on the first malaria attack of each…
- Trial name
- SMART-CURE (NCT00699920)
- Testing
- Coarsucam, Coartem
- Where
- Uganda
- Volunteers
- 413 people
- Sponsor
- Sanofi
Malaria
Safety and Efficacy Study of IV Artesunate to Treat Malaria
The purpose of this study is to determine how GMP IV Artesunate is metabolized and cleared by individuals with uncomplicated malaria infection and to determine how fast it eliminates malaria infection from the body.
- Trial name
- NCT00298610
- Testing
- Artesunate, Malarone
- Where
- Kenya
- Volunteers
- 30 people
- Sponsor
- U.S. Army Medical Research and Development Command
Malaria (Plasmodium Falciparum)
Safety and Efficacy of Imatinib in Combination With Artemether-Lumefantrine for Uncomplicated Malaria
This study is investigating an innovative approach to treating uncomplicated malaria by adding a drug called Imatinib to the current standard of care, Artemether + Lumefantrine (AL).
- Trial name
- NCT07559370
- Testing
- Artemether lumefantrine tablets, Artemether Lumefantrine and Imatinib Mesylate
- Where
- Kenya
- Volunteers
- 1,116 people
- Sponsor
- Victoria Biomedical Research Institute
Vivax Malaria
Chloroquine Population Pharmacokinetics in Pre and Post-partum Women
For the treatment of P.vivax the standard treatment is chloroquine. There is a growing body of evidence suggesting that pregnant women may require different doses of drugs, including antimalarials due to the physiological changes…
- Trial name
- KCP (NCT01546961)
- Testing
- Chloroquine
- Where
- Thailand
- Volunteers
- 49 people
- Sponsor
- University of Oxford
Plasmodium Vivax Malaria Without Complication, Plasmodium Falciparum Malaria (Uncomplicated)
Ethiopian Antimalarial Therapeutic Efficacy Study 2026
Background: The WHO recommends monitoring the efficacy of antimalarial drugs at least once every two years after implementation.
- Trial name
- TES2026 (NCT07840898)
- Testing
- Artemether-Lumefantrine + Primaquine and Chloroquine + Primaquine
- Where
- Ethiopia
- Volunteers
- 1,200 people
- Sponsor
- Ethiopian Public Health Institute
Malaria
Ethiopia Malaria Therapeutic Efficacy Study
In this stdy, patients aged above 6 months with symptomatic malaria presenting to health centers will be enrolled for treatment with artemether-lumefantrine for P.
- Trial name
- NCT01052584
- Testing
- Chloroquine- P. vivax, Artemether-Lumefantrine: P. vivax, Artemether-lumefantrine: P. falciparum
- Where
- 2 sites in Ethiopia
- Volunteers
- 354 people
- Sponsor
- Centers for Disease Control and Prevention
Plasmodium Falciparum Malaria
Multi-Centre Trial Comparing Three Artemisinin-Based Combination Treatments on P. Falciparum Malaria
The purpose of this open randomised multi-centre clinical trial is to test the hypothesis that three pills of the fixed dose combination artesunate/sulfamethoxypyrazine/pyrimethamine, administered over 24 hours is not inferior in…
- Trial name
- NCT00484900
- Testing
- Co-Arinate FDC, Coartem
- Where
- 4 sites in Cameroon, Mali and 2 more
- Volunteers
- 1,390 people
- Sponsor
- Dafra Pharma
Malaria Vivax
Efficacy of Chloroquine-Primaquine Treatment for Uncomplicated Plasmodium Vivax Malaria
The study was designed to evaluate the current efficacy of this combination therapy against P. vivax, given the possibility of misuse or inadequate adherence to the regimen due to its lengthy treatment duration, in one of a…
- Trial name
- CQ-PQ (NCT07753967)
- Testing
- CQ-PQ
- Where
- Ethiopia
- Volunteers
- 192 people
- Sponsor
- Jimma University
Plasmodium Falciparum Malaria
Efficacy of Artesunate + Amodiaquine Versus Artemether-lumefantrine for Falciparum Malaria in Zanzibar, 2005
The primary objective of the study was to determine the PCR-APCR up to day 42 in children <60 months of age, weighing ≥5kg with uncomplicated malaria, treated with either artesunate+ amodiaquine (ASAQ) or artemether-lumefantrine…
- Trial name
- ACOII (NCT03768908)
- Testing
- Artemether-lumefantrine, Artesunate + Amodiaquine
- Volunteers
- 359 people
- Sponsor
- Professor Anders Björkman
Malaria
Randomised Trial of 3 Artemisinin Combination Therapy for Malaria in Pregnancy
This is a randomised, open label trial, comparing standard dose of dihydroartemisinin-piperaquine (DP) with standard fixed artesunate-mefloquine regimen (MAS3) and with a longer regimen of artemether-lumefantrine (ALN+) in the…
- Trial name
- DMA (NCT01054248)
- Testing
- dihydroartemisinin-piperaquine, Artesunate-mefloquine, arthemeter-lumefantrin
- Where
- Thailand
- Volunteers
- 511 people
- Sponsor
- University of Oxford
Plasmodium Falciparum Infection
Dose Ranging Study of Ferroquine With Artesunate in African Adults and Children With Uncomplicated Plasmodium Falciparum Malaria
Primary objective: To assess the Day 28 efficacy defined as the percentage of patients with no parasitic recrudescence, of 3 treatment groups - 3 dose levels of ferroquine associated with artesunate - for a 3-day treatment.
- Trial name
- FARM (NCT00988507)
- Testing
- Ferroquine (SSR97193), artesunate
- Where
- 10 sites in Benin, Burkina Faso and 4 more
- Volunteers
- 440 people
- Sponsor
- Sanofi
Malaria, Falciparum
Randomised Efficacy Study of Two Artemether-Lumefantrine Oral Formulations for the Treatment of Uncomplicated P. Falciparum Malaria
The purpose of this study is to compare the safety and efficacy in children aged 6 - 59 months with uncomplicated malaria, treated with either conventional artemether/lumefantrine tablets(Coartem®) or artemether/ lumefantrine…
- Trial name
- NCT00529867
- Testing
- Artemether/lumefantrine tablets, Artemether/Lumefantrine suspension
- Where
- Kenya
- Volunteers
- 267 people
- Sponsor
- Dafra Pharma